Indivior PLC

Investor Presentation • May 23, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9881F

Indivior PLC

23 May 2017

Indivior's Shaun Thaxter to present at the Jefferies Global Healthcare Conference on June 6th

Slough, UK, May 23rd, 2017 - Indivior PLC (LON: INDV) today announced that Shaun Thaxter, CEO, will present at the Jefferies Global Healthcare Conference on June 6th, 2017, at 10:00 a.m. local time, in New York City. Mark Crossley, CFO, and Jason Thompson, VP of Investor Relations, will also be in attendance. Thaxter will review Indivior's business and outlook. The presentation will be webcast live, and the broadcast and presentation materials will be available on the "Investors" section of Indivior's website (www.indivior.com) on June 6th, 2017.

About Indivior

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy, health policy and evidence-based best practice models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction including alcohol use disorder, cocaine intoxication and schizophrenia. Headquartered in the United States in Richmond, VA., Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more.

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: +1 804-423-8916 or jason.thompson@indivior.com 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCAJMTTMBJTBRR